ANTIBODIES AND ANTI-IDIOTYPES TO NEUROLEPTIC DRUGS

多巴胺能（D2）和多巴胺能（S2）药物的单克隆抗体 （精神抑制剂）和受体将使用独特型的策略： 抗独特型分子模拟 这种策略使用一种抗体 针对D2或S2拮抗剂（配体）的（独特型），以作为 用于随后产生抗独特型抗体的“模具”，所述抗独特型抗体可 构成抗配体结合位点的“内部图像”，从而 在分子上模拟原始配体。 一系列单克隆 多巴胺能配体氟哌啶醇和匹莫齐特的抗体已经被 目前正在生产和后续的抗独特型抗体 测试. 这些受体结合抗体将用于受体免疫中。 表征、定位和纯化研究。 这些研究 将提供宝贵的信息工具， 独特型：抗独特型模拟和抗受体抗体在 神经系统疾病。

Monoclonal antibodies to dopaminergic (D2) and serotoninergic (S2) drugs (neuroleptics) and receptors will be made using the strategy of idiotype: anti-idiotype molecular mimicry. This strategy employs an antibody (idiotype) directed against D2 or S2 antagonists (ligands) to act as a "mold" for the subsequent production of an anti-idiotype antibody which can constitute an "internal image" of the anti-ligand binding site, and thereby mimic, in molecular terms, the original ligand. A collection of monoclonal antibodies to the dopaminergic ligands haloperidol and pimozide have been produced and subsequent anti-idiotype antibodies are currently being tested. These receptor binding antibodies will be used in receptor characterization, localization and purification studies. These studies will provide valuable information tools for the study of idiotype:anti-idiotype mimicry and the role of anti-receptor antibodies in nervous system diseases.